Publications
-
Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/hepatitis C
Citation: Bedimo R, Kang M, Tebas P, Overton ET, Hollabaugh K, McComsey G, Bhattacharya D, Evans C, Brown TT, Taiwo B. Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses. 2016 Apr;32(4):325-8. doi: 10.1089/AID.2015.0204. Epub 2015 Nov 24. PMID: 26499270. PMCID: PMC4817562.
Date: 04/15/2016
Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite
Citation: Shivakoti R, Yang WT, Berendes S, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Lama JR, Cardoso SW, Sugandhavesa P, Balagopal A, Gupte N, Semba RD, Campbell TB, Bollinger RC, Gupta A; NWCS 319 and PEARLS Study Team. Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, is associated with HIV disease progression in resource-constrained settings. J Infect Dis. 2016 Apr 1;213(7):1074-8. doi: 10.1093/infdis/jiv573. Epub 2015 Nov 29. PMID: 26621909 PMCID. PMC4779305.
Date: 04/01/2016
Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s.
Citation: McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20. PMID: 26797215. PMCID: PMC4787610.
Date: 04/01/2016
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating
Citation: Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, MBBCh, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1198-209. doi: 10.1016/S0140-6736(16)00546-8. PMID: 27025337. PMCID: PMC4931281.
Date: 03/19/2016
Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: Consensus
Citation: Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: Consensus statements from an international expert panel. Clin Infect Dis. 2016 Mar 15;62(6):761-769. doi: 10.1093/cid/civ991. Epub 2015 Dec 9. PMID: 26658057. PMCID: PMC4772846.
Date: 03/15/2016
Tuberculosis risk among medical trainees, Pune, India
Citation: Basavaraj A, Chandanwale A, Patil A, Kadam D, Joshi S, Gupte N, McIntire K, Jain D, Dalal H, Badave R, DeLuca A, Gupta A, Bollinger R, Mave V. Tuberculosis risk among medical trainees, Pune, India. Emerg Infect Dis. 2016 Mar;22(3):541-3. doi: 10.3201/eid2203.151673.
Date: 03/15/2016
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and
Citation: Natsag J, Kendall MA, Sellmeyer DE, McComsey GA, Brown TT. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density. HIV Med. 2016 Mar;17(3):196-205. doi: 10.1111/hiv.12291. Epub 2015 Jul 16. PMID: 26177791 PMCID. PMC4715784.
Date: 03/15/2016
Inflammation and change in body weight with antiretroviral therapy initiation
Citation: Mave V, Erlandson KM, Gupte N, Balgopal A, Asmuth DM, Campbell TB, Smeaton L, Kumarasamy N, Hakim J, Santos B, Riviere C, Hosseinipour MC, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Tripathy S, Mwelase N, Berendes S, Andrade BB, Thomas DL, Bollinger RC, Gupta A, and the ACTG PEARLS and NWCS 319 Study Team. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016 Jul 1;214(1):65-72. doi: 10.1093/infdis/jiw096. Epub 2016 Mar 8. PMID: 26962236. PMCID: PMC4907416.
Date: 03/08/2016
Soluble CD14: an independent biomarker for the risk of mother-to-child transmission of HIV in a
Citation: Shivakoti R, Gupta A, Ray JC, Uprety P, Gupte N, Bhosale R, Mave V, Patil S, Balasubramanian U, Kinikar A, Bharadwaj R, Bollinger RC, Persaud D. Soluble CD14: an independent biomarker for the risk of mother-to-child transmission of HIV in a setting of preexposure and postexposure antiretroviral prophylaxis. J Infect Dis. 2016 Mar 1;213(5):762-5. doi: 10.1093/infdis/jiv479. Epub 2015 Oct 6. PMID: 26443598. PMCID: PMC4747613
Date: 03/01/2016
Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART)
Citation: Shivakoti R, Christian P, Yang WT, Gupte N, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Berendes S, Lama JR,Cardoso SW, Sugandhavesa P, Tang AM, Semba RD, Campbell TB, Gupta A; for the NWCS 319 and PEARLS Study Team. Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr. 2016 Feb;35(1):183-9. doi: 10.1016/j.clnu.2015.02.002. PMID: 25703452. PMCID: PMC4531105.
Date: 02/15/2016
- ‹ First < 12 13 14 15 16 > Last ›